Theranostics: Peptide-based Theranostics

A promising approach to improve both diagnostic sensitivity/specificity and definitive therapy is the evolving field of tumor-targeting peptides. Tumor-targeting peptides have the potential to enable more precise diagnostic imaging while simultaneously advancing new therapeutic paradigms for next generation image-guided surgery, tumor-specific chemotherapeutic delivery and tumor-selective targeted theranostic radiotherapy.


Peptide-based Theranostics

Xiaoyuuan (Shawn) Chen, Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA

Peptide drugs are a small niche market, but actually growing rather rapidly. Peptide theranostics aim to identify the receptor and its targeting peptide. Peptide analogs are designed and prepared with the intention of optimizing the biological activity and metabolic behavior, as well as the chemical conjugation that would make it work functionally as either a diagnostic imaging agent or a therapeutic.


Image-guided receptor targeted radionuclide therapy for cancer. Alpha-particle theranostics from academic discovery to clinical use as a small biotech startup

Michael Schultz, The University of Iowa and Viewpoint Molecular Targeting

Talk outline:

  • University start-ups
  • “Academic Entrepreneurism”
  • MC1R targeting
  • Translational realities


Multivalent theranostic nanoprobe for the PSMA-targeted delivery of a therapeutic peptide to prostate cancer

J. Manuel Perez, Cedar Sinai Medical Center, Los Angeles, CA, USA

Talk outline:

  • Prostate specific membrane antigen (PSMA)
  • Folate-conjugated polymeric nanoparticles
  • CT20p, a therapeutic peptide that targets Chaperonin

Home Widget 3

This is your third home widget box. To edit please go to Appearance > Widgets and choose 8th widget from the top in area 8 called Home Widget 3. Title is also manageable from widgets as well.